The University of Chicago Header Logo

Connection

Stanley Liauw to Humans

Back to Details
This is a "connection" page, showing publications Stanley Liauw has written about Humans.
Stanley Liauw
Connection Strength
1.234
Humans
  1. Multidisciplinary Collaboration is Key. Int J Radiat Oncol Biol Phys. 2023 Dec 01; 117(5):1047-1048.
    View in: PubMed
    Score: 0.032
  2. Monitoring Intrafraction Motion of the Prostate During Radiation Therapy: Suggested Practice Points From a Focused Review. Pract Radiat Oncol. 2024 Mar-Apr; 14(2):146-153.
    View in: PubMed
    Score: 0.031
  3. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2023 01 01; 115(1):202-213.
    View in: PubMed
    Score: 0.029
  4. Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup. J Urol. 2022 06; 207(6):1236-1245.
    View in: PubMed
    Score: 0.028
  5. Chemoradiation for Anal Cancer: Clinical Outcomes and Strategies to Optimize the Therapeutic Ratio According to HPV Status. Semin Radiat Oncol. 2021 10; 31(4):349-360.
    View in: PubMed
    Score: 0.027
  6. High-risk Prostate Cancer Treated with Radiation Therapy: Opportunities to Reduce Cancer Mortality after Biochemical Failure. Eur Urol. 2021 08; 80(2):147-148.
    View in: PubMed
    Score: 0.026
  7. A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity. Cancer. 2021 08 01; 127(15):2631-2640.
    View in: PubMed
    Score: 0.026
  8. Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. J Natl Cancer Inst. 2020 08 01; 112(8):847-854.
    View in: PubMed
    Score: 0.025
  9. Improved outcomes after radiotherapy for prostate cancer: Anticoagulation, antiplatelet therapy, and platelet count as key factors in disease progression. Cancer Med. 2020 07; 9(13):4667-4675.
    View in: PubMed
    Score: 0.025
  10. PI-RADS score is associated with biochemical control and distant metastasis in men with intermediate-risk and high-risk prostate cancer treated with radiation therapy. Urol Oncol. 2020 06; 38(6):600.e1-600.e8.
    View in: PubMed
    Score: 0.024
  11. Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy. Eur Urol. 2019 11; 76(5):686-692.
    View in: PubMed
    Score: 0.023
  12. Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. Clin Genitourin Cancer. 2019 Feb; 17(1):e12-e18.
    View in: PubMed
    Score: 0.022
  13. Pretreatment multiparametric MRI is independently associated with biochemical outcome in men treated with radiation therapy for prostate cancer. Urol Oncol. 2018 10; 36(10):471.e11-471.e18.
    View in: PubMed
    Score: 0.022
  14. Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy. PLoS One. 2018; 13(3):e0194234.
    View in: PubMed
    Score: 0.021
  15. A Pancreatic Predicament. Int J Radiat Oncol Biol Phys. 2017 10 01; 99(2):296-297.
    View in: PubMed
    Score: 0.021
  16. The use of Hormonal Therapy to Augment Radiation Therapy in Prostate Cancer: An Update. Curr Urol Rep. 2017 Jul; 18(7):50.
    View in: PubMed
    Score: 0.020
  17. External Validation and Optimization of International Consensus Clinical Target Volumes for Adjuvant Radiation Therapy in Bladder Cancer. Int J Radiat Oncol Biol Phys. 2017 03 15; 97(4):740-746.
    View in: PubMed
    Score: 0.019
  18. Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):306-312.
    View in: PubMed
    Score: 0.019
  19. Endorectal MRI for risk classification of localized prostate cancer: Radiographic findings and influence on treatment decisions. Urol Oncol. 2016 09; 34(9):416.e15-21.
    View in: PubMed
    Score: 0.019
  20. Bladder dose-volume parameters are associated with urinary incontinence after postoperative intensity modulated radiation therapy for prostate cancer. Pract Radiat Oncol. 2016 Sep-Oct; 6(5):e179-e185.
    View in: PubMed
    Score: 0.018
  21. Patterns of Failure After Radical Cystectomy for pT3-4 Bladder Cancer: Implications for Adjuvant Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Apr 01; 94(5):1031-9.
    View in: PubMed
    Score: 0.018
  22. Quality of Life after Post-Prostatectomy Intensity Modulated Radiation Therapy: Pelvic Nodal Irradiation Is Not Associated with Worse Bladder, Bowel, or Sexual Outcomes. PLoS One. 2015; 10(10):e0141639.
    View in: PubMed
    Score: 0.018
  23. Image-guided radiation therapy for prostate cancer: A computed tomography-based assessment of fiducial marker migration between placement and 7 days. Pract Radiat Oncol. 2015 Jul-Aug; 5(4):241-7.
    View in: PubMed
    Score: 0.017
  24. The impact of hormonal therapy on sexual quality of life in men receiving intensity modulated radiation therapy for prostate cancer. Pract Radiat Oncol. 2015 May-Jun; 5(3):e223-e228.
    View in: PubMed
    Score: 0.017
  25. Late toxicity and quality of life after definitive treatment of prostate cancer: redefining optimal rectal sparing constraints for intensity-modulated radiation therapy. Cancer Med. 2014 Aug; 3(4):954-61.
    View in: PubMed
    Score: 0.016
  26. Tobacco use and external beam radiation therapy for prostate cancer: Influence on biochemical control and late toxicity. Cancer. 2013 Aug 01; 119(15):2807-14.
    View in: PubMed
    Score: 0.015
  27. Herpes zoster and radiation therapy: what radiation oncologists need to know about diagnosing, preventing, and treating herpes zoster. Pract Radiat Oncol. 2014 Jan-Feb; 4(1):58-64.
    View in: PubMed
    Score: 0.015
  28. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus. Urology. 2013 Jun; 81(6):1196-201.
    View in: PubMed
    Score: 0.015
  29. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med. 2013 Feb 20; 5(173):173sr2.
    View in: PubMed
    Score: 0.015
  30. Effects of aspirin on cancer initiation and progression. Expert Rev Anticancer Ther. 2013 Feb; 13(2):115-7.
    View in: PubMed
    Score: 0.015
  31. Validation of normal tissue complication probability predictions in individual patient: late rectal toxicity. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):1103-9.
    View in: PubMed
    Score: 0.015
  32. Radiation dose =54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation. Radiat Oncol. 2012 Sep 13; 7:156.
    View in: PubMed
    Score: 0.014
  33. Unresectable Hepatocellular Carcinoma Due to Portal Venous Thrombosis: Focal Stereotactic Body Radiation Therapy Can Promote Resectability. J Gastrointest Cancer. 2012 Sep; 43 Suppl 1:S202-7.
    View in: PubMed
    Score: 0.014
  34. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012 Oct 01; 30(28):3540-4.
    View in: PubMed
    Score: 0.014
  35. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):378-84.
    View in: PubMed
    Score: 0.014
  36. Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. Ann Surg Oncol. 2012 Aug; 19(8):2471-6.
    View in: PubMed
    Score: 0.014
  37. Image-guided radiotherapy using surgical clips as fiducial markers after prostatectomy: a report of total setup error, required PTV expansion, and dosimetric implications. Radiother Oncol. 2012 May; 103(2):270-4.
    View in: PubMed
    Score: 0.013
  38. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):235-41.
    View in: PubMed
    Score: 0.013
  39. Prolongation of total treatment time because of infrequently missed days of treatment is not associated with inferior biochemical outcome after dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):751-7.
    View in: PubMed
    Score: 0.013
  40. Radiotherapeutic strategies in the management of low-risk prostate cancer. ScientificWorldJournal. 2010 Sep 14; 10:1854-69.
    View in: PubMed
    Score: 0.013
  41. External beam radiotherapy for prostate cancer: urinary outcomes for men with high International Prostate Symptom Scores (IPSS). Int J Radiat Oncol Biol Phys. 2011 Jul 15; 80(4):1080-6.
    View in: PubMed
    Score: 0.012
  42. Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Mar 15; 79(4):1022-8.
    View in: PubMed
    Score: 0.012
  43. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010 Jun 01; 28(16):2653-9.
    View in: PubMed
    Score: 0.012
  44. The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. Cancer. 2010 Apr 01; 116(7):1820-6.
    View in: PubMed
    Score: 0.012
  45. External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity. Int J Radiat Oncol Biol Phys. 2010 Jul 15; 77(4):1060-5.
    View in: PubMed
    Score: 0.012
  46. Late rectal toxicity after prostate brachytherapy: influence of supplemental external beam radiation on dose-volume histogram analysis. Brachytherapy. 2010 Apr-Jun; 9(2):131-6.
    View in: PubMed
    Score: 0.012
  47. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2010 May 01; 77(1):125-30.
    View in: PubMed
    Score: 0.012
  48. Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer. Technol Cancer Res Treat. 2009 Jun; 8(3):201-6.
    View in: PubMed
    Score: 0.012
  49. External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity? Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):755-60.
    View in: PubMed
    Score: 0.012
  50. Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores. Cancer. 2009 Apr 15; 115(8):1784-90.
    View in: PubMed
    Score: 0.011
  51. The use of capecitabine in the combined-modality therapy for rectal cancer. Clin Colorectal Cancer. 2008 Mar; 7(2):99-104.
    View in: PubMed
    Score: 0.011
  52. Salvage radiotherapy after postprostatectomy biochemical failure: does pretreatment radioimmunoscintigraphy help select patients with locally confined disease? Int J Radiat Oncol Biol Phys. 2008 Aug 01; 71(5):1316-21.
    View in: PubMed
    Score: 0.011
  53. Isolated neck recurrence after definitive radiotherapy for node-positive head and neck cancer: salvage in the dissected or undissected neck. Head Neck. 2007 Aug; 29(8):715-9.
    View in: PubMed
    Score: 0.010
  54. Definitive radiotherapy for head-and-neck cancer with radiographically positive retropharyngeal nodes: incomplete radiographic response does not necessarily indicate failure. Int J Radiat Oncol Biol Phys. 2006 Nov 15; 66(4):1017-21.
    View in: PubMed
    Score: 0.010
  55. Radiotherapy after subtotally resected or recurrent ganglioglioma. Int J Radiat Oncol Biol Phys. 2007 Jan 01; 67(1):244-7.
    View in: PubMed
    Score: 0.010
  56. Whole-abdomen radiotherapy for non-Hodgkin's lymphoma using twice-daily fractionation. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1440-5.
    View in: PubMed
    Score: 0.010
  57. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):669-73.
    View in: PubMed
    Score: 0.009
  58. Postradiotherapy neck dissection for lymph node-positive head and neck cancer: the use of computed tomography to manage the neck. J Clin Oncol. 2006 Mar 20; 24(9):1421-7.
    View in: PubMed
    Score: 0.009
  59. The effect of intravenous contrast on intensity-modulated radiation therapy dose calculations for head and neck cancer. Am J Clin Oncol. 2005 Oct; 28(5):456-9.
    View in: PubMed
    Score: 0.009
  60. Inflammatory breast carcinoma: outcomes with trimodality therapy for nonmetastatic disease. Cancer. 2004 Mar 01; 100(5):920-8.
    View in: PubMed
    Score: 0.008
  61. Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
    View in: PubMed
    Score: 0.008
  62. Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. Urology. 2003 Jun; 61(6):1204-10.
    View in: PubMed
    Score: 0.008
  63. Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. J Clin Oncol. 2023 02 20; 41(6):1307-1317.
    View in: PubMed
    Score: 0.007
  64. Blood Prostate-specific Antigen by Volume of Benign, Gleason Pattern 3 and 4 Prostate Tissue. Urology. 2022 12; 170:154-160.
    View in: PubMed
    Score: 0.007
  65. Reflections on Anthony Zietman From Gastrointestinal Cancer and Physics Editors. Int J Radiat Oncol Biol Phys. 2021 Dec 01; 111(5):1114-1117.
    View in: PubMed
    Score: 0.007
  66. Can Pre-treatment Quantitative Multi-parametric MRI Predict the Outcome of Radiotherapy in Patients with Prostate Cancer? Acad Radiol. 2022 07; 29(7):977-985.
    View in: PubMed
    Score: 0.007
  67. The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation. Int J Radiat Oncol Biol Phys. 2022 05 01; 113(1):66-76.
    View in: PubMed
    Score: 0.007
  68. Goals of care discussions: perceptions of radiation and medical oncologists. Support Care Cancer. 2021 Dec; 29(12):7279-7288.
    View in: PubMed
    Score: 0.007
  69. Comfort Level of US Radiation Oncology Graduates: Assessment of Transition to Independent Clinical Practice. J Cancer Educ. 2021 04; 36(2):278-283.
    View in: PubMed
    Score: 0.007
  70. Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2021 03 15; 109(4):953-963.
    View in: PubMed
    Score: 0.006
  71. 18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE. Pract Radiat Oncol. 2020 Sep - Oct; 10(5):354-362.
    View in: PubMed
    Score: 0.006
  72. Utilizing the TrueBeam Advanced Imaging Package to monitor intrafraction motion with periodic kV imaging and automatic marker detection during VMAT prostate treatments. J Appl Clin Med Phys. 2020 Mar; 21(3):184-191.
    View in: PubMed
    Score: 0.006
  73. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. J Urol. 2019 08; 202(2):272-281.
    View in: PubMed
    Score: 0.006
  74. A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). BMC Cancer. 2019 Jun 13; 19(1):572.
    View in: PubMed
    Score: 0.006
  75. Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization. Am J Clin Oncol. 2019 04; 42(4):382-390.
    View in: PubMed
    Score: 0.006
  76. Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and Sézary syndrome. Br J Haematol. 2019 07; 186(2):377-379.
    View in: PubMed
    Score: 0.006
  77. Long term control and preservation of renal function after multiple courses of stereotactic body radiation therapy for renal cell carcinoma. Can J Urol. 2019 04; 26(2):9743-9745.
    View in: PubMed
    Score: 0.006
  78. Optimizing the Role of Surgery and Radiation Therapy in Urethral Cancer Based on Histology and Disease Extent. Int J Radiat Oncol Biol Phys. 2018 10 01; 102(2):304-313.
    View in: PubMed
    Score: 0.005
  79. Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncol. 2018 05 10; 4(5):e175230.
    View in: PubMed
    Score: 0.005
  80. Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy. Am J Clin Oncol. 2017 Dec; 40(6):612-620.
    View in: PubMed
    Score: 0.005
  81. Gastrointestinal Cancers: Timing Is Everything. Int J Radiat Oncol Biol Phys. 2017 12 01; 99(5):1051-1058.
    View in: PubMed
    Score: 0.005
  82. Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. Eur Urol. 2018 07; 74(1):99-106.
    View in: PubMed
    Score: 0.005
  83. Managing Cancer Relapse After Radical Prostatectomy: Adjuvant Versus Salvage Radiation Therapy. Urol Clin North Am. 2017 Nov; 44(4):597-609.
    View in: PubMed
    Score: 0.005
  84. Creation of a Novel Digital Rectal Examination Evaluation Instrument to Teach and Assess Prostate Examination Proficiency. J Surg Educ. 2018 Mar - Apr; 75(2):434-441.
    View in: PubMed
    Score: 0.005
  85. High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir =0.2 to Select Men for Short-term Hormonal Therapy. Am J Clin Oncol. 2017 Aug; 40(4):348-352.
    View in: PubMed
    Score: 0.005
  86. Contemporary management of men with high-risk localized prostate cancer in the United States. Prostate Cancer Prostatic Dis. 2017 09; 20(3):283-288.
    View in: PubMed
    Score: 0.005
  87. Radiation oncology residency selection: A postgraduate evaluation of factor importance and survey of variables associated with job securement. Pract Radiat Oncol. 2017 Nov - Dec; 7(6):425-432.
    View in: PubMed
    Score: 0.005
  88. ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer. Am J Clin Oncol. 2017 02; 40(1):1-10.
    View in: PubMed
    Score: 0.005
  89. ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. Brachytherapy. 2017 Mar - Apr; 16(2):266-276.
    View in: PubMed
    Score: 0.005
  90. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):1046-1053.
    View in: PubMed
    Score: 0.005
  91. Gastrointestinal Cancers-Changing the Standard for Rectal Cancer and Establishing a New Standard for Liver Tumors. Int J Radiat Oncol Biol Phys. 2016 07 01; 95(3):930-6.
    View in: PubMed
    Score: 0.005
  92. A Prostate Fossa Contouring Instructional Module: Implementation and Evaluation. J Am Coll Radiol. 2016 Jul; 13(7):835-841.e1.
    View in: PubMed
    Score: 0.005
  93. ACR Appropriateness Criteria Renal Cell Carcinoma Staging. J Am Coll Radiol. 2016 May; 13(5):518-25.
    View in: PubMed
    Score: 0.005
  94. Management of Low-Stage Testicular Seminoma. Urol Clin North Am. 2015 Aug; 42(3):287-98.
    View in: PubMed
    Score: 0.004
  95. Combined-modality therapy for rectal cancer: analysis of potential differences in disease presentation, treatment adherence, and treatment outcome according to race. Am J Clin Oncol. 2014 Apr; 37(2):122-5.
    View in: PubMed
    Score: 0.004
  96. Clinical outcomes for gastric cancer following adjuvant chemoradiation utilizing intensity modulated versus three-dimensional conformal radiotherapy. PLoS One. 2014; 9(1):e82642.
    View in: PubMed
    Score: 0.004
  97. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol. 2013 Dec; 36(6):589-95.
    View in: PubMed
    Score: 0.004
  98. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1473-9.
    View in: PubMed
    Score: 0.003
  99. A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age. Am J Clin Oncol. 2010 Dec; 33(6):619-23.
    View in: PubMed
    Score: 0.003
  100. The role of radiotherapy in locally advanced pancreatic carcinoma. Nat Rev Gastroenterol Hepatol. 2010 Aug; 7(8):437-47.
    View in: PubMed
    Score: 0.003
  101. Prostate cancer modality time trend analyses from 1973 to 2004: a Surveillance, Epidemiology, and End Results registry analysis. Am J Clin Oncol. 2010 Apr; 33(2):168-72.
    View in: PubMed
    Score: 0.003
  102. Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials? Nat Clin Pract Gastroenterol Hepatol. 2009 Jan; 6(1):38-46.
    View in: PubMed
    Score: 0.003
  103. Age and grade trends in prostate cancer (1974-2003): a Surveillance, Epidemiology, and End Results Registry analysis. Am J Clin Oncol. 2008 Aug; 31(4):375-8.
    View in: PubMed
    Score: 0.003
  104. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology. 2008 Dec; 72(6):1298-302; discussion 1302-4.
    View in: PubMed
    Score: 0.003
  105. Lymph node-positive head and neck cancer treated with definitive radiotherapy: can treatment response determine the extent of neck dissection? Cancer. 2008 Mar 01; 112(5):1076-82.
    View in: PubMed
    Score: 0.003
  106. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007 Oct 10; 25(29):4581-6.
    View in: PubMed
    Score: 0.003
  107. The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients. Clin Med Res. 2007 Jun; 5(2):123-31.
    View in: PubMed
    Score: 0.003
  108. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007 May 20; 25(15):2035-41.
    View in: PubMed
    Score: 0.003
  109. Grade migration in prostate cancer: an analysis using the Surveillance, Epidemiology, and End Results registry. Prostate Cancer Prostatic Dis. 2007; 10(4):347-51.
    View in: PubMed
    Score: 0.003
  110. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004 Mar 17; 291(11):1325-32.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.